Loading people...
Camille Ridel is an Investor at Sanofi Ventures, the corporate venture capital arm of multinational pharmaceutical company Sanofi. In this capacity, she specializes in strategic life sciences investments, evaluating early-stage companies across immunology, neurology, rare diseases, vaccines, and digital health. Ridel recently participated in a $17.0 million Series B funding round for Character Biosciences in September 2025. She executed this specific transaction alongside notable industry co-investors, including Michele Park and the team at Pontifax Venture Capital. Within the corporate venture group, she collaborates with key firm personnel such as Jason Hafler, Daniel Mansuri, Jim Trenkle, and Cris De Luca to identify emerging therapeutic platforms for the corporate portfolio. Her current focus remains centered on deploying strategic capital into innovative biotechnology and digital health startups that directly align with broader pharmaceutical development objectives.
Camille Ridel is a key investor at Sanofi Ventures, where she plays a pivotal role in identifying and nurturing the next generation of healthcare innovators. Sanofi Ventures is dedicated to investing in early stage and growth stage companies that are developing novel therapeutics, digital health solutions, and other transformative technologies aligned with Sanofi's strategic interests. Camille's work directly contributes to Sanofi's mission of bringing life changing medicines and solutions to patients worldwide.
At Sanofi Ventures, Camille's investment focus is broad yet strategic, encompassing areas such as biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health platforms. She is particularly interested in companies that demonstrate strong scientific foundations, address significant unmet medical needs, and possess the potential for scalable impact. Her expertise helps Sanofi Ventures identify opportunities that not only offer financial returns but also foster synergistic partnerships with Sanofi's core business units, accelerating innovation from discovery to patient access.
Camille's career background is rooted in a deep understanding of the life sciences industry, likely combining scientific acumen with a strong grasp of venture capital principles and corporate strategy. While specific details of her prior roles are not provided, it is common for investors in corporate venture capital to have experience in scientific research, business development within pharmaceutical companies, or prior roles in traditional venture capital firms. This diverse background equips her with the ability to evaluate complex scientific propositions, assess market potential, and guide startups through critical development stages.
Although specific notable investments by Camille Ridel are not publicly detailed, her contributions are integral to Sanofi Ventures' overall portfolio success. The fund has a track record of backing companies that go on to make significant advancements in their respective fields, from novel drug discovery platforms to innovative patient management tools. Camille's involvement ensures that Sanofi Ventures continues to be a leading force in supporting the entrepreneurial ecosystem within healthcare, driving forward solutions that promise to reshape the future of medicine and improve global health outcomes.
Camille Ridel is an investor at Sanofi Ventures, the corporate venture capital arm of the global pharmaceutical company Sanofi. She focuses on identifying and investing in innovative healthcare and life science startups.
Camille Ridel invests in early stage and growth stage companies within the healthcare and life sciences sectors. Her focus areas include biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health solutions that align with Sanofi's strategic interests.
Camille Ridel works at Sanofi Ventures, which is the corporate venture capital fund associated with Sanofi, a leading global pharmaceutical company.
